The Acute Myeloid Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals. Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2024 | Safety and tolerability of AMG 330, a bispecific T-cell engager, in adult patients with R/R AML
Farhad Ravandi, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, presents the safety and tolerability of AMG 330 in adults with relapsed/refractory (R/R) acute myeloid leukemia (AML). In a Phase I dose escalation trial (NCT02520427), AMG 330 elicited responses but was associated with toxicities such as cytokine release syndrome (CRS) and infusion reactions. Dr Ravandi is unsure whether this agent will move into further development, as focusing efforts on developing bispecific antibodies with AML-specific targets may confer greater therapeutic benefit. This interview took place at the 29th Congress of the European Hematology Association (EHA) in Madrid, Spain.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Transcript
Using bispecific antibodies in hematological malignancies is becoming widespread, with some of the bispecifics being approved in various diseases. We have conducted a number of studies using bispecifics in AML and AMG 330 was one of the earlier ones that was recently published. This was a Phase I dose escalation trial. We did see responses, but there was also some toxicity, including cytokine release syndrome and infusion reactions...
Using bispecific antibodies in hematological malignancies is becoming widespread, with some of the bispecifics being approved in various diseases. We have conducted a number of studies using bispecifics in AML and AMG 330 was one of the earlier ones that was recently published. This was a Phase I dose escalation trial. We did see responses, but there was also some toxicity, including cytokine release syndrome and infusion reactions. I think the target, which is CD33, is a viable target, although a more AML-specific target, if such a thing exists, will likely to be more beneficial in terms of the therapeutic window of such bispecific agents. And so perhaps we will have future bispecifics with higher potential. In terms of this agent, I’m not sure if this is going to go further in development
Read more...
Disclosures
Research funding: Astex/Taiho.
